Aim: To evaluate the survival of patients with unresectable perihilar cholangiocarcinoma (PHC) treated with multimodal palliative approaches.
Patients And Methods: thirty-two patients were enrolled in a multimodal protocol including: bilateral biliary drainage; Yridium-192 intraluminal brachytherapy (BT); metal biliary stenting; external-beam radiotherapy (EBRT); systemic chemotherapy (ChT). All patients underwent BT and biliary stenting: this was the only treatment for 14 patients, it was combined with EBRT in 11, and with EBRT and ChT in seven. Mean and median survival, complication rates and duration of hospital stay were calculated for each group.
Results: BT with EBRT and ChT obtained the best median (15 months) and one year (71.42%) survival followed by BT with EBRT (14 months and 63.63%, respectively). BT with EBRT in a total dose of 54-60 Gy, with or without ChT, led to a significantly higher median survival rate (14 months) than that for BT alone (seven months).
Conclusion: BT with EBRT, with or without ChT, improves survival and should be considered as a suitable alternative to palliative surgery for patients with unresectable perihilar cholangiocarcinoma.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of Clinical Characteristics and Treatment on Cholangiocarcinoma Prognosis in Southern Thailand.
Cancer Med
December 2024
Gastroenterology and Hepatology Unit, Division of Internal Medicine, Faculty of Medicine, Prince of Songkla University, Hat Yai, Songkhla, Thailand.
Article Synopsis
- Cholangiocarcinoma (CCA) patients in Southern Thailand exhibit late-stage diagnoses, with 59.4% diagnosed at TMN stage IV, and the overall median survival is only 5-6 months.
- The study reviewed 223 CCA patients between 2018 and 2021, identifying that intrahepatic CCA (iCCA) was the most common subtype (49.3%), and only 15.1% of patients were considered resectable.
- Key factors affecting survival included TMN stage, with a higher risk of mortality linked to late-stage diagnosis, while systemic chemotherapy and palliative biliary drainage improved outcomes for unresectable patients.
Gemcitabine-cisplatin induction treatment in patients with locally advanced perihilar cholangiocarcinoma (IMPACCA): A prospective registration study.
Eur J Surg Oncol
November 2024
Amsterdam UMC, Location University of Amsterdam, Department of Surgery, Amsterdam, the Netherlands; Cancer Center Amsterdam, Amsterdam, the Netherlands. Electronic address:
Background: Induction treatment may be beneficial in patients with unresectable locally advanced perihilar cholangiocarcinoma (LAPCCA). Prospective studies are currently lacking. This study aimed to assess the feasibility and efficacy of gemcitabine and cisplatin as induction treatment in patients with unresectable LAPCCA.
View Article and Find Full Text PDFTime to Surgery Does Not Affect the Survival Outcome in Patients with Perihilar Cholangiocarcinoma.
Ann Surg Oncol
December 2024
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Article Synopsis
- * Patients were divided into long-TTS (≥64 days) and short-TTS (<64 days) groups, with the long-TTS group showing higher rates of preoperative biliary infections and portal vein embolization but comparable overall survival rates between the groups.
- * Despite a lower rate of potentially curative resections in the long-TTS group, TTS did not have an association with survival outcomes for those undergoing potentially curative procedures.
Resectability and survival outcome in real world practice of 720 cholangiocarcinoma patients: intrahepatic, perihilar and distal cholangiocarcinoma.
World J Surg Oncol
November 2024
Department of Surgery, Sunpasitthiprasong Hospital, 122 Sunpasit Road, Nai Mueang Subdistrict, Mueang Ubon Ratchathani District, Ubon Ratchathani, 34000, Thailand.
Background: Cholangiocarcinoma (CCA) is an adenocarcinoma of the hepatobiliary system, which can be classified into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA). Surgical resection is the curative treatment for all subtypes of CCA. This study evaluates patients with CCA who underwent surgery and determines factors that impact their survival.
View Article and Find Full Text PDFRadiation-Emitting metallic stent for unresectable bismuth type III or IV perihilar cholangiocarcinoma: a multicenter randomized trial.
Int J Surg
September 2024
Center of Interventional Radiology & Vascular Surgery, Department of Radiology, Zhongda Hospital, Medical School, Southeast University, Nanjing, China.
Article Synopsis
- The study compares the effectiveness and safety of radiation-emitting metallic stents (REMS) combined with hepatic arterial infusion chemotherapy (HAIC) versus self-expandable metallic stents (SEMS) with HAIC for patients with unresectable perihilar cholangiocarcinoma (pCCA).
- Results showed that patients using REMS-HAIC had a median overall survival of 10.2 months, significantly longer than the 6.7 months for SEMS-HAIC.
- Additionally, REMS-HAIC demonstrated better time to symptomatic progression and stent patency, while having an acceptable safety profile, with no major differences in jaundice relief or severe adverse events between the two groups.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!